CANCER EPIDEMIOLOGY PROGRAM The Cancer Epidemiology program studies environmental, genetic, and molecular risks for cancer and cancer outcomes to identify priorities for public health and clinical intervention. The program has three aims: (1) Risk- Based Prevention and Early Detection: To identify opportunities for risk-based prevention and early detection of cancer; (2) Treatment, Outcomes and Survivorship: To improve cancer treatment, outcomes, and survivorship through epidemiologic and clinical research that leads to evidence-based interventions; (3) Integrative Molecular Epidemiology: To deepen understanding of cancer etiology, heterogeneity, and survivorship through integrative human molecular and histopathologic studies of precursor lesions and tumors. A major cross-cutting theme is addressing the epidemiology of health disparities. As a comprehensive cancer center in an economically, socially, and racially diverse state, CE is well-poised to address health equity. Across these aims, we use multidimensional North Carolina studies and conduct cross-program research to yield high impact findings. Members have expertise in population-based epidemiology, data linkage, pharmacoepidemiology, survey research, clinical research, screening, molecular and biomarker research, translational preclinical research, sociology, pathology, genomics, data science, computer science, and statistical and epidemiologic methods. Research resources include population-based studies of breast, colon, prostate, head and neck cancer as well as registries for breast and lung screening. Many of these studies participate in large national and international data-sharing initiatives and consortia. The Program brings value to the Center through study resources that collect exposure and outcome data, and biospecimens, a unique shared resource (Statewide Cancer Data), and expertise in epidemiologic methods. The Program is supported by UNC Lineberger?s investments in faculty recruitments, shared resources and developmental funds. The UNC Lineberger strategic plan emphasis on optimizing cancer outcomes in North Carolina has led to significant investment across population sciences and is expanding in new areas in coming years including endometrium and bladder, with sustained support for ongoing data collection in breast cancer and head and neck cancers. The CE Program consists of 33 members who are associated with 9 departments at UNC- Chapel Hill and affiliated institutions. During the last funding period, program members have published 776 cancer-related articles, 24% were inter-programmatic and 19% were intra-programmatic (34% collaborative). In 2019, our program members held grants totaling $10.0M (direct cost) in cancer-relevant extramural funding, including $5.2M (direct costs) from the NCI and $3.0M other peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089819
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications